Cormorant Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Cormorant Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100,000	Closed	-$10.1M	–	91
2021 Q3	$10.1M	Sell	100,000 -68,150	-41%	-$7.99M	0.41%	54
2021 Q2	$23.8M	Sell	168,150 -231,850	-58%	-$26.2M	0.81%	35
2021 Q1	$39.9M	Sell	400,000 -100,000	-20%	-$11.7M	0.89%	28
2020 Q4	$61.8M	Buy	500,000 +50,000	+11%	+$6.57M	1.47%	24
2020 Q3	$43.8M	Buy	450,000 +50,000	+13%	+$6.25M	1.69%	22
2020 Q2	$62.4M	Sell	400,000 -87,206	-18%	-$13.3M	2.38%	13
2020 Q1	$70.3M	Sell	487,206 -329,194	-40%	-$63.6M	3.27%	7
2019 Q4	$167M	Sell	816,400 -3,369	-0.4%	-$615K	6.66%	2
2019 Q3	$65.8M	Buy	819,769 +13,619	+2%	+$1.16M	4.01%	5
2019 Q2	$76.1M	Buy	806,150 +191,150	+31%	+$16.5M	4.37%	4
2019 Q1	$52.6M	Sell	615,000 -59,251	-9%	-$4.92M	3.55%	8
2018 Q4	$37.8M	Buy	674,251 +14,251	+2%	+$870K	3.07%	9
2018 Q3	$54M	Buy	660,000 +210,000	+47%	+$14.8M	3.51%	8
2018 Q2	$15.7M	Hold	450,000	–	–	1.16%	29
2018 Q1	$9.23M	Buy	450,000 +250,000	+125%	+$6.43M	0.69%	29
2017 Q4	$5.66M	Sell	200,000 -188,574	-49%	-$5.26M	0.59%	35
2017 Q3	$12.1M	Buy	+388,574	New	+$11.7M	2.13%	15

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cormorant Asset Management's RETA Position: Q4 2021 in Review

Cormorant Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 100,000 shares — an estimated $10.1M sold.

Cormorant Asset Management first reported a position in RETA in Q3 2017 and held it in 17 quarters. The position peaked at $167M in Q4 2019. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Cormorant Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Cormorant Asset Management sold 100,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $10.1M.
Cormorant Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 17 quarters.
Cormorant Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $167M in Q4 2019.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.